Three Serum Proteins Accurately Detect Kidney Cancer
Levels of three serum proteins are much higher in kidney cancer patients, enabling a highly accurate diagnosis of the disease.
Renal Cell Carcinoma
Controversies and Challenges Surrounding Treatment for Renal Cell Carcinoma
Despite concerns that sunitinib may hasten disease progression after therapy, a recent trial refutes that claim, while other patient-related challenges of treating RCC have come to light.
No OS Difference Between Tivozanib and Sorafenib for Advanced Renal Cell Carcinoma
No significant difference in overall survival was found between tivozanib and sorafenib in patients with advanced renal cell carcinoma, according to research presented at the 2013 Genitourinary Cancers Symposium.
Biopsy-Based Algorithm Found Accurate for Small Renal Masses
Compared with final pathology, biopsy of small renal masses can be accurately used in a treatment algorithm to direct management, according to research published in the February issue of The Journal of Urology.
Erythrocyte Sedimentation Rate May Predict Kidney Cancer Survival
Erythrocyte sedimentation rate and anemia predict survival among patients with clear cell renal cell carcinoma.
RSNA: Percutaneous Image-Guided Biopsy is ‘Safe and Highly Diagnostic’ for Renal Masses
Image-guided percutaneous core biopsy can accurately differentiate between benign and malignant renal masses with few complications.
RSNA: RECIST, Choi, and Modified Choi Criteria Fail to Predict Progression-Free Survival in Everolimus-Treated RCC
In patients with metastatic renal cell carcinoma treated with the mTOR inhibitor everolimus, RECIST criteria, Choi and modified Choi criteria fail to predict PFS.
Survival Advantage for Whites With Renal Cell Carcinoma
Compared with whites, proportionally more blacks were diagnosed with RCC under age 50 and with localized cancer.
ASTRO: Stereotactic Radiosurgery for Primary Renal Cancer Deemed a ‘Viable Option’
The first prospective study of stereotactic radiosurgery for the treatment of patients with localized primary renal cancer has found it to be well tolerated.
ESMO: Pazopanib Effective Against Metastatic Renal Cell Carcinoma
Targeted drug pazopanib’s efficacy in controlling metastatic renal cell carcinoma (mRCC) is similar to that of sunitinib, but with lower incidences of patient fatigue and skin sores.
- Loading...
Loading...
Loading... 
Loading...